Novartis MS Franchise Boosted After Fending Off Last Gilenya Challenge
Still Company's Third-Biggest Seller
The Swiss firm expects no generic versions of Gilenya in the US market "for at least the next two years" after a court again ruled against HEC Pharma, the only remaining company challenging its patent.
